The developers promise that the immune response of the new vaccine will be more active and last longer. Its release is scheduled for the end of the year.
According to the head of the pharmaceutical company Sanofi France, Olivier Bogillot, the vaccine has entered the third phase of research and may be available by December.
Bogillot also noted that, unlike Pfizer-BioNTech, AstraZeneca, Moderna, and Janssen, the French vaccine will not use mRNA technology. It will be based on a recombinant protein, as in modern flu vaccinations. According to him, in combination with a special substance — an adjuvant — the immune response will be more active and last longer.
“This is what we use for influenza vaccination, a proven technology that we have been using for several years,” he said.
Among the advantages of the French coronavirus vaccine, the head of the company called inexpensive production and more lenient storage requirements. Bogillot noted that the low cost of the drug will help less developed countries accelerate the vaccination campaign.
Earlier it was reported that the third dose of the COVID-vaccine Sinovac increases the number of antibodies in the body by 10-20 times.